Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared With Placebo in Healthy Participants

NCT06575153 is registered in ClinicalTrials.gov with Arialys Therapeutics as lead sponsor.

NCT NCT06575153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ART5803 Compared With Placebo in Healthy Participants
Lead sponsor
Arialys Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2024
Completion date
October 31, 2025
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune encephalitis